Skip to main content

RT @TheLancetRheum: Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffus

Nov 09, 2020 2:07 pm
Social Author Name
The Lancet Rheumatology
Tweet Content
Results of the NOVESA phase 2 trial of Ziritaxestat (an autotaxin inhibitor) in patients with diffuse cutaneous #SSc presented by @sclerodermaUM at #ACR20 Improvements in mRSS and ACR-CRISS with Ziritaxestat, but not in lung outcomes. 31/33 patients continue in OLE https://t.co/kVQWN1s8Zy
Show on Archive Page
On
Display in Search Results
On
×